93 related articles for article (PubMed ID: 30980038)
1. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.
Hammarsten P; Josefsson A; Thysell E; Lundholm M; Hägglöf C; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Granfors T; Wikström P; Bergh A
Mod Pathol; 2019 Sep; 32(9):1310-1319. PubMed ID: 30980038
[TBL] [Abstract][Full Text] [Related]
2. Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins AC; Gusterson B; Szijgyarto Z; Haviland J; Griffin C; Stuttle C; Daley F; Corbishley CM; Dearnaley DP; Hall E; Somaiah N;
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):309-315. PubMed ID: 29559283
[TBL] [Abstract][Full Text] [Related]
3. 'High proliferative cribriform prostate cancer' defines a patient subgroup with an inferior prognosis.
Bogaard M; Skotheim RI; Maltau AV; Kidd SG; Lothe RA; Axcrona K; Axcrona U
Histopathology; 2023 Dec; 83(6):853-869. PubMed ID: 37501635
[TBL] [Abstract][Full Text] [Related]
4. Can we use Ki67 expression to predict prostate cancer aggressiveness?
Maia R; Santos GAD; Reis S; Viana NI; Pimenta R; Guimarães VR; Recuero S; Romão P; Leite KRM; Srougi M; Passerotti CC
Rev Col Bras Cir; 2022; 49():e20223200. PubMed ID: 35792806
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic Role and Prognostic Impact of PSAP Immunohistochemistry: A Tissue Microarray Study on 31,358 Cancer Tissues.
Tribian LS; Lennartz M; Höflmayer D; de Wispelaere N; Dwertmann Rico S; von Bargen C; Kind S; Reiswich V; Viehweger F; Lutz F; Bertram V; Fraune C; Gorbokon N; Weidemann S; Hube-Magg C; Menz A; Uhlig R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Steurer S; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C
Diagnostics (Basel); 2023 Oct; 13(20):. PubMed ID: 37892063
[TBL] [Abstract][Full Text] [Related]
6. [Molecular subtypes provide possibilities for precision medicine in a advanced prostate cancer].
Wikström P; Bergh A; Josefsson A; Thysell E; Welén K
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38656744
[TBL] [Abstract][Full Text] [Related]
7. Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
Cancel M; Crottes D; Bellanger D; Bruyère F; Mousset C; Pinault M; Mahéo K; Fromont G
Prostate; 2024 Mar; 84(4):358-367. PubMed ID: 38112233
[TBL] [Abstract][Full Text] [Related]
8. [Ki67 in the prognosis of prostate cancer].
Huang T; Liu JJ; Zhang JW; Zhu ZC; Wang T; Cai L; Chen ZQ
Zhonghua Nan Ke Xue; 2019 Dec; 25(12):1088-1092. PubMed ID: 32251559
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.
Thysell E; Vidman L; Ylitalo EB; Jernberg E; Crnalic S; Iglesias-Gato D; Flores-Morales A; Stattin P; Egevad L; Widmark A; Rydén P; Bergh A; Wikström P
Mol Oncol; 2019 Aug; 13(8):1763-1777. PubMed ID: 31162796
[TBL] [Abstract][Full Text] [Related]
10. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts.
Song Z; Zhou Q; Zhang JL; Ouyang J; Zhang ZY
World J Clin Cases; 2024 Jan; 12(1):32-41. PubMed ID: 38292624
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Neutrophil to Lymphocyte Ratio (NLR), a cogent clinical adjunct for Ki-67 in breast cancer.
Arora R; Alam F; Zaka-Ur-Rab A; Maheshwari V; Alam K; Hasan M
J Egypt Natl Canc Inst; 2023 Dec; 35(1):43. PubMed ID: 38143264
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer genetic risk and associated aggressive disease in men of African ancestry.
Soh PXY; Mmekwa N; Petersen DC; Gheybi K; van Zyl S; Jiang J; Patrick SM; Campbell R; Jaratlerdseri W; Mutambirwa SBA; Bornman MSR; Hayes VM
Nat Commun; 2023 Dec; 14(1):8037. PubMed ID: 38052806
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic profiles of intact tissues reflect clinically relevant prostate cancer subtypes.
Dudka I; Lundquist K; Wikström P; Bergh A; Gröbner G
J Transl Med; 2023 Nov; 21(1):860. PubMed ID: 38012666
[TBL] [Abstract][Full Text] [Related]
14. MRI Radiomics-Based Machine Learning Models for Ki67 Expression and Gleason Grade Group Prediction in Prostate Cancer.
Qiao X; Gu X; Liu Y; Shu X; Ai G; Qian S; Liu L; He X; Zhang J
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760505
[TBL] [Abstract][Full Text] [Related]
15. Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
Advani R; Luzzi S; Scott E; Dalgliesh C; Weischenfeldt J; Munkley J; Elliott DJ
Oncogene; 2023 Oct; 42(43):3161-3168. PubMed ID: 37752235
[TBL] [Abstract][Full Text] [Related]
16. Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.
Yu X; Liu R; Song L; Gao W; Wang X; Zhang Y
Front Oncol; 2023; 13():1165732. PubMed ID: 37456243
[TBL] [Abstract][Full Text] [Related]
17. Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy.
He J; Che B; Li P; Li W; Huang T; Chen P; Liu M; Li G; Zhong S; Tang K
Front Surg; 2023; 10():1140883. PubMed ID: 37091270
[TBL] [Abstract][Full Text] [Related]
18. Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer.
Muj C; Mukhopadhyay S; Jana P; Kondapi AK
Cancer Chemother Pharmacol; 2023 May; 91(5):375-387. PubMed ID: 36977771
[TBL] [Abstract][Full Text] [Related]
19. Tumor immune contexture predicts recurrence after prostatectomy and efficacy of androgen deprivation and immunotherapy in prostate cancer.
Han S; Shi T; Liao Y; Chen D; Yang F; Wang M; Ma J; Li H; Xu Y; Zhu T; Chen W; Wang G; Han Y; Xu C; Wang W; Cai S; Zhang X; Xing N
J Transl Med; 2023 Mar; 21(1):194. PubMed ID: 36918939
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
